Search
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalThe cDNA coding for rasburicase was cloned from a strain of _Aspergillus flavus_.
Categories: Detoxifying Agents for Antineoplastic TreatmentProducts: FASTURTEC POWDER FOR SOLUTION FOR INFUSION 1.5 mg/vialEpoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...
Products: VELETRI POWDER FOR SOLUTION FOR INFUSION 0.5MG/VIAL, VELETRI POWDER FOR SOLUTION FOR INFUSION 1.5MG/VIALNadroparin
go.drugbank.com/drugs/DB08813ApprovedInvestigationalWithdrawnIt is derived from porcine sources and has a mean molecular size of 5000 daltons.
Products: FRAXIPARINE 0.4ML FER, FRAXIPARINE 0.6ML FERDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnThe FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications. … In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Powder for Injection 500mg, DORIBAX 500 MG (Doripenem) for InjectionIsavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalThis formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns … [A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersProducts: CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MGAnifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalalter patient responses in the experimental and placebo groups; and patient populations were largely homogenous, which may have increased the odds of success of the trial. … of the clinical trials use different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids, which may
Categories: Type I Interferon Receptor AntagonistProducts: SAPHNELO 300MG CONCENTRATE FOR SOLUTION FOR INFUSIONIpilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Products: YERVOY 5 mg/ml concentrate for solution for infusionLixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalLixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLProducts: LYXUMIA (SOLUTION FOR INJECTION 10 MCG), LYXUMIA (SOLUTION FOR INJECTION 20 MCG)Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717, A253722] After receiving an EMA Committee for Medicinal Products for Human Use (CHMP) recommendation in December 2022, tremelimumab was approved for combined use with [durvalumab].[L46188] … CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells.
Products: Imjudo Concentrate for Solution for Intravenous Infusion 20 mg/mLFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigationalFremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsProducts: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5ML